Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,061 stopped studies mapped to Malignant Neoplasm of Unknown Primary and descendants · 91% state a reason
Over the 2,061 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01720563 | A Phase II Trial of PG2 in Patients With Advanced Pharyngeal or Laryngeal Squamous Cell… | Phase 2 | terminated | Nov 2, 2012 | PhytoHealth Corporation | Change study drug dosage form | Other (stated, no rule matched) |
| NCT02419495 | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple… | Phase 1 | terminated | Apr 17, 2015 | M.D. Anderson Cancer Center | Administratively Complete | Other (stated, no rule matched) |
| NCT06393751 | Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment… | Phase 1 / Phase 2 | withdrawn | May 1, 2024 | National Cancer Institute (NCI) | Other - Protocol moved to Withdrawn | Other (stated, no rule matched) |
| NCT04849364 | Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients…(PERSEVERE) | Phase 2 | terminated | Apr 19, 2021 | Bryan Schneider, MD | Funder Decision | Other (stated, no rule matched) |
| NCT04152018 | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. | Phase 1 | terminated | Nov 5, 2019 | Pfizer | Study termination was based on strategic considerations and not due to specific safety reasons or a… | Safety / toxicity |
| NCT03432741 | Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With… | Phase 1 | terminated | Feb 14, 2018 | Mayo Clinic | funding - sponsor filing Chapter 11 bankruptcy | Funding |
| NCT05287347 | Panc CA Risk Model & Biomarker Testing In High-Risk Cohort | — | withdrawn | Mar 18, 2022 | Beth Israel Deaconess Medical Center | Lack of funding | Funding |
| NCT04442126 | A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Jun 22, 2020 | Numab Therapeutics AG | A business decision was made to discontinue further enrollment. There were no safety concerns that… | Safety / toxicity |
| NCT06361758 | Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC | Phase 2 | withdrawn | Apr 12, 2024 | Shanghai Zhongshan Hospital | The PI has initiated a global multicenter Phase II clinical trial in the same direction, conducted… | Other (stated, no rule matched) |
| NCT06077487 | Ketamine-assisted Therapy for Advanced GI Cancer | Phase 4 | terminated | Oct 11, 2023 | Brian Anderson, MD | Slow Accrual | Enrollment / accrual |
| NCT01125449 | Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease | Phase 2 | withdrawn | May 18, 2010 | Situs Cancer Research Center | Awaiting response from FDA as to status of parenteral ascorbic acid manufactured by Bioniche… | Drug supply |
| NCT03742349 | Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple… | Phase 1 | terminated | Nov 15, 2018 | Novartis Pharmaceuticals | This was a sponsor decision and was not a consequence of any safety concern | Safety / toxicity |
| NCT04252859 | [18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma | Phase 2 | terminated | Feb 5, 2020 | University of Utah | PI is leaving the institution. | Other (stated, no rule matched) |
| NCT04738786 | Clinical Study Evaluating the Proper Surgical Safety Margin for Early Stage Oral Tongue… | N/A | terminated | Feb 4, 2021 | Samsung Medical Center | Due to Korean medical crisis, Resident strike, Patient referral (tongue cancer patients) to… | Enrollment / accrual |
| NCT01938833 | Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer | Phase 1 / Phase 2 | terminated | Sep 10, 2013 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Closed by Sponsor | Other (stated, no rule matched) |
| NCT03534141 | Mild Hypothermia and Acute Kidney Injury in Liver Transplantation(MHALT) | N/A | terminated | May 23, 2018 | University of California, San Francisco | Terminated 9/24/23 at 85% target enrollment due to slow accrual of subjects. The decline in… | Enrollment / accrual |
| NCT04926181 | Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine… | Phase 2 | terminated | Jun 15, 2021 | Rahul Aggarwal | Funding | Funding |
| NCT02756130 | Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade… | Phase 1 / Phase 2 | withdrawn | Apr 29, 2016 | Jonsson Comprehensive Cancer Center | funding was not secured | Funding |
| NCT04633278 | CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head… | Phase 2 | terminated | Nov 18, 2020 | Regeneron Pharmaceuticals | Business Decision | Sponsor / business decision |
| NCT05311176 | A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in…(nextHERIZON) | Phase 2 | terminated | Apr 5, 2022 | Imugene Limited | Study was discontinued because of slow enrollment and organizational priorities and not because of… | Safety / toxicity |
| NCT05930938 | Study Comparing RT With Cetuximab + Xevinapant to RT With Cetuximab-placebo in Patients…(XXL_2022-01) | Phase 3 | terminated | Jul 5, 2023 | Groupe Oncologie Radiotherapie Tete et Cou | toxicity | Safety / toxicity |
| NCT04579757 | Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Oct 8, 2020 | Hutchmed | Study terminated by sponsor | Other (stated, no rule matched) |
| NCT04732286 | A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With… | Phase 3 | terminated | Feb 1, 2021 | Hoffmann-La Roche | The study was completed as pre-specified in the protocol. Study was terminated only for… | Other (stated, no rule matched) |
| NCT04329221 | Immunotherapy Before Transplantation for Skin Cancer Prevention in Organ Transplant… | Phase 2 | withdrawn | Apr 1, 2020 | Massachusetts General Hospital | The study was withdrawn due to lack of financial support. | Funding |
| NCT04642287 | Immunotherapy After Transplantation for Skin Cancer Prevention in Organ Transplant… | Phase 2 | withdrawn | Nov 24, 2020 | Massachusetts General Hospital | The study was withdrawn due to lack of financial support. | Funding |
| NCT02414100 | Patient Derived Cancer Cell Lines in Identifying Molecular Changes in Patients With… | — | withdrawn | Apr 10, 2015 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | No subjects were enrolled. Study team was not able to grow cell lines for the tumors. | Enrollment / accrual |
| NCT02671552 | Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Kidney… | Early Phase 1 | withdrawn | Feb 2, 2016 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Terminated by the IRB | Other (stated, no rule matched) |
| NCT06644079 | Window of Opportunity Study of Topical Tranexamic Acid for Cutaneous Squamous Cell… | Phase 2 | withdrawn | Oct 16, 2024 | University of Florida | Study not moving forward due to upcoming PI departure | Other (stated, no rule matched) |
| NCT05757492 | Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients… | Phase 1 | terminated | Mar 7, 2023 | Coherus Oncology, Inc. | The study was terminated for strategic reasons (not for safety concerns) | Safety / toxicity |
| NCT03053960 | Helical CT, PET/CT, MRI, and CBCT Alone or in Combination in Predicting Jaw Invasion in… | — | terminated | Feb 15, 2017 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Terminated by IRB | Other (stated, no rule matched) |
| NCT03374852 | CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced… | Phase 2 | withdrawn | Dec 15, 2017 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | PI Left institution on 8/6/2018 and study has been final reported with IRB. Never opened to accrual | Investigator |
| NCT02939807 | A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular… | Phase 2 | withdrawn | Oct 20, 2016 | Medical University of South Carolina | study is being rewritten for different disease population | Other (stated, no rule matched) |
| NCT04595981 | Chemo-embolization for Head and Neck Cancer | Phase 2 | withdrawn | Oct 22, 2020 | University of Alabama at Birmingham | No staff or funding to do the study. | Funding |
| NCT03581500 | Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in… | Phase 2 | withdrawn | Jul 10, 2018 | M.D. Anderson Cancer Center | Committee could not find that the regulatory approval are met to re-approve this study. | Other (stated, no rule matched) |
| NCT04301011 | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors(RAPTOR) | Phase 1 | terminated | Mar 9, 2020 | Turnstone Biologics, Corp. | Sponsor decision | Sponsor / business decision |
| NCT05448677 | Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First…(ABE-LIVER) | Phase 2 | terminated | Jul 7, 2022 | University Hospital, Grenoble | Study terminated due to recruitement issues | Enrollment / accrual |
| NCT03610490 | Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or… | Phase 2 | terminated | Aug 1, 2018 | M.D. Anderson Cancer Center | Lack of Efficacy | Efficacy / futility |
| NCT04870112 | A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer…(SCope-D1) | Phase 1 | terminated | May 3, 2021 | AstraZeneca | AstraZeneca has decided to stop further enrollment and the study was terminated when all patients… | Safety / toxicity |
| NCT04893759 | A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors | Phase 1 | terminated | May 19, 2021 | Ascentage Pharma Group Inc. | Company Strategy | Sponsor / business decision |
| NCT05322135 | A Pilot Study of Glutamine PET Imaging of Head and Neck Squamous Cell Carcinoma | Early Phase 1 | terminated | Apr 11, 2022 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT05737706 | Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation | Phase 1 | terminated | Feb 21, 2023 | Mirati Therapeutics Inc. | Formulation challenges | Other (stated, no rule matched) |
| NCT05608369 | Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC(HPV) | Phase 2 | withdrawn | Nov 8, 2022 | Case Comprehensive Cancer Center | PI left | Investigator |
| NCT03829501 | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab… | Phase 1 / Phase 2 | terminated | Feb 4, 2019 | Kymab Limited | Early discontinuation based on strategic sponsor decision not driven by any safety concerns. | Safety / toxicity |
| NCT05003856 | Radiofrequency Ablation for the Treatment of Benign or Low Risk Thyroid Nodule | N/A | terminated | Aug 12, 2021 | M.D. Anderson Cancer Center | Administrativley Complete, 75%\<Participants | Other (stated, no rule matched) |
| NCT06094842 | Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen… | Phase 1 | withdrawn | Oct 23, 2023 | Fred Hutchinson Cancer Center | Study closed before opening to accrual | Enrollment / accrual |
| NCT04108481 | Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer(iRE-C) | Phase 1 | terminated | Sep 30, 2019 | University of Iowa | DSMC-directed closure | Other (stated, no rule matched) |
| NCT05494866 | A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients with Advanced Stage…(IntenSify) | Phase 1 | terminated | Aug 10, 2022 | German Cancer Research Center | lack of efficacy paired with high toxicity | Safety / toxicity |
| NCT03636607 | Diagnostic Significance of Single Center, Open and Prospective Evaluation of… | N/A | withdrawn | Aug 17, 2018 | Fifth Affiliated Hospital, Sun Yat-Sen University | No participents enrolled | Enrollment / accrual |
| NCT03889093 | Radioembolization of Primary and Secondary Liver Malignancies and The Effect On The… | N/A | terminated | Mar 26, 2019 | University of Minnesota | PI Left Institution | Investigator |
| NCT05336721 | A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC | Phase 2 | terminated | Apr 20, 2022 | Chipscreen Biosciences, Ltd. | During the enrollment period of this project, due to the increasing proportion of patients… | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jun 4, 2025source: clinicaltrials